These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9108186)

  • 1. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis.
    Smith A; Weber A; Pandher R; Williams-Warren J; Cohen ML; Ramsey B
    Infection; 1997; 25(2):106-8. PubMed ID: 9108186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic disposition of sequential intravenous/oral ciprofloxacin in pediatric cystic fibrosis patients with acute pulmonary exacerbation.
    Rubio TT; Miles MV; Lettieri JT; Kuhn RJ; Echols RM; Church DA
    Pediatr Infect Dis J; 1997 Jan; 16(1):112-7; discussion 123-6. PubMed ID: 9002120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ciprofloxacin pharmacokinetics in young cystic fibrosis patients after repeated oral doses.
    Odoul F; Le Guellec C; Giraut C; de Gialluly C; Marchand S; Paintaud G; Saux MC; Rolland JC; Autret-Leca E
    Therapie; 2001; 56(5):519-24. PubMed ID: 11806288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of ciprofloxacin in pediatric cystic fibrosis patients.
    Schaefer HG; Stass H; Wedgwood J; Hampel B; Fischer C; Kuhlmann J; Schaad UB
    Antimicrob Agents Chemother; 1996 Jan; 40(1):29-34. PubMed ID: 8787874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics of ciprofloxacin and ofloxacin in cystic fibrosis patients.
    Pedersen SS; Jensen T; Hvidberg EF
    J Antimicrob Chemother; 1987 Oct; 20(4):575-83. PubMed ID: 3479419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral ciprofloxacin in the treatment of pseudomonas exacerbations of paediatric cystic fibrosis: clinical efficacy and safety evaluation using magnetic resonance image scanning.
    Redmond A; Sweeney L; MacFarland M; Mitchell M; Daggett S; Kubin R
    J Int Med Res; 1998 Dec; 26(6):304-12. PubMed ID: 10399112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study.
    Stass H; Weimann B; Nagelschmitz J; Rolinck-Werninghaus C; Staab D
    Clin Ther; 2013 Oct; 35(10):1571-81. PubMed ID: 24054830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and pharmacokinetics of ciprofloxacin dry powder for inhalation in cystic fibrosis: a phase I, randomized, single-dose, dose-escalation study.
    Stass H; Delesen H; Nagelschmitz J; Staab D
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):106-15. PubMed ID: 25050456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluoroquinolones in the treatment of cystic fibrosis: a critical appraisal.
    LeBel M
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):316-24. PubMed ID: 1907546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased oral bioavailability of ciprofloxacin in cystic fibrosis patients.
    Christensson BA; Nilsson-Ehle I; Ljungberg B; Lindblad A; Malmborg AS; Hjelte L; Strandvik B
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2512-7. PubMed ID: 1489195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral bioequivalence of three ciprofloxacin formulations following single-dose administration: 500 mg tablet compared with 500 mg/10 mL or 500 mg/5 mL suspension and the effect of food on the absorption of ciprofloxacin oral suspension.
    Shah A; Liu MC; Vaughan D; Heller AH
    J Antimicrob Chemother; 1999 Mar; 43 Suppl A():49-54. PubMed ID: 10225572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis.
    Montgomery MJ; Beringer PM; Aminimanizani A; Louie SG; Shapiro BJ; Jelliffe R; Gill MA
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3468-73. PubMed ID: 11709326
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ciprofloxacin pharmacokinetics and oral absorption of generic ciprofloxacin tablets in dogs.
    Papich MG
    Am J Vet Res; 2012 Jul; 73(7):1085-91. PubMed ID: 22738062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative bioequivalence and pharmacokinetics of ciprofloxacin in healthy male subjects.
    Khan MK; Khan MF
    Pak J Pharm Sci; 2009 Jan; 22(1):1-7. PubMed ID: 19168412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ciprofloxacin monotherapy for acute pulmonary exacerbations of cystic fibrosis.
    Goldfarb J; Stern RC; Reed MD; Yamashita TS; Myers CM; Blumer JL
    Am J Med; 1987 Apr; 82(4A):174-9. PubMed ID: 3555032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis.
    Guillot E; Sermet I; Ferroni A; Chhun S; Pons G; Zahar JR; Jullien V
    Pharmacotherapy; 2010 Dec; 30(12):1252-8. PubMed ID: 21114393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [A cross-over study on the effectiveness of ofloxacin and ciprofloxacin administered orally].
    Kurz CC; Marget W; Harms K; Bertele RM
    Infection; 1986; 14 Suppl 1():S82-6. PubMed ID: 2937740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral ciprofloxacin affects the pharmacokinetics of paracetamol in saliva.
    Issa MM; Nejem RM; El-Abadla NS
    Clin Drug Investig; 2006; 26(4):223-6. PubMed ID: 17163255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy and tolerance of intravenously and orally administered ciprofloxacin in cystic fibrosis patients with acute exacerbations of lung infection.
    Strandvik B; Hjelte L; Lindblad A; Ljungberg B; Malmborg AS; Nilsson-Ehle I
    Scand J Infect Dis Suppl; 1989; 60():84-8. PubMed ID: 2756354
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.